First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Javier Torres-Jiménez, Ana Paisan, Mariano Ponz-Sarvise, Bruno Bockorny, Marta Gil-Martin, Ricardo Cubedo, Luis G. Paz-Ares, Ana Landa-Magdalena, Gerburg M. Wulf, Paula Sàbat, Fabio Franco Perez, Myriam Fabre, Alvaro Gonzalez, Patricia Gonzalez, Isabel Egaña, Susana Roman, Laureano Simon, Ignacio Garcia-Ribas, Ander Urruticoechea
Institutions: Hospital Universitario 12 De Octubre, Osakidetza, Onkologikoa, Clinica Universidad de Navarra, Universidad de Navarra, Beth Israel Deaconess Medical Center, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center Madrid, Oncomatryx (Spain)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410816228